Aktienanalyse zu Fresenius Medical Care AG (FMS)FMSFresenius Medical Care AG

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers. It operates in the Healthcare sector.

Fresenius Medical Care AG is not a good buy right now. The current price is $21.06, and the RSI is at 31.076, indicating oversold conditions. However, the forward P/E ratio is 8.5763, suggesting potential undervaluation, but the recent downgrades from analysts and a significant 23.17% decline over the past year raise concerns. The main risk is the potential for further declines in U.S. dialysis volumes, as indicated by BNP Paribas's downgrade.